Streetbeat News

DXR

Daxor Corporation

https://www.daxor.com

Industry

Medical - Instruments & Supplies

Daxor Corporation, a medical device company, provides blood volume measurement technology focused on blood volume testing. The company develops and markets BVA-100 Blood Volume Analyzer, a diagnostic blood test to provide safe, accurate, objective quantification of blood volume status and composition compared to patient-specific norms for used in a broad range of medical and surgical conditions. The company was formerly known as Idant Corporation and changed its name to Daxor Corporation in May 1973. Daxor Corporation was incorporated in 1971 and is headquartered in Oak Ridge, Tennessee.

Open

9.02

Mkt cap

45M

Volume

190K

High

9.72

P/E Ratio

7.99

52-wk high

10.04

Low

8.80

Div yield

N/A

52-wk low

7.11

Daxor Corporation (NASDAQ:DXR) reported growth in Q4 2023 through new sales of its BVA-100 Blood Volume Diagnostic analyzers to hospital systems and increased utilization at existing accounts across the U.S. The company's ezBVA Lab Service was highlighted as a key factor in driving this growth and adoption. Sales wins included analyzer purchases and rentals at major healthcare systems in Georgia, Wisconsin, and a multi-state academic health center, as well as an extension of the ezBVA Lab service in New Jersey. CEO Michael Feldschuh emphasized the company's focus on broadening commercial reach and improving patient outcomes.

Portfolio Pulse from Benzinga Newsdesk

February 07, 2024 | 1:06 pm

Daxor Corporation has been granted a second patent by the United States Patent and Trademark Office for a clinical guidance system for blood volume management. This system uses unique blood volume metrics and related clinical measures to assist in fluid management interventions.

Portfolio Pulse from Benzinga Newsdesk

January 09, 2024 | 1:04 pm

Daxor Corporation has submitted its new Blood Volume Analyzer (BVA) system to the FDA for clearance, with expectations for potential approval in the first half of 2024. The new BVA system is designed to deliver faster, simpler, and bedside results, aligning with the company's mission to improve healthcare through optimal fluid management.

Portfolio Pulse from Benzinga Newsdesk

January 02, 2024 | 1:33 pm

Daxor Corporation has announced the presentation of data from a Phase I NIH-sponsored trial at the American Heart Association Annual Meeting. The data is likely to be significant for the company's profile in the medical community and could influence investor perception.

Portfolio Pulse from Benzinga Newsdesk

November 13, 2023 | 1:03 pm

Daxor Corporation (NASDAQ:DXR), a global leader in blood volume measurement technology, has been granted a new patent for a system that provides remote blood volume monitoring. The patent covers various methods, including wearable devices like smartwatches. The technology will help optimize ongoing care based on the patient's evolving blood volume status. This addition to Daxor's intellectual property portfolio is part of the company's strategy to fuel future product development.

Portfolio Pulse from Benzinga Newsdesk

November 09, 2023 | 1:20 pm

Daxor Corporation (NASDAQ:DXR) has announced new data from Banner University Medicine validating the benefits of the company's BVA-100 diagnostic blood test for ambulatory patients with advanced heart failure. The data was presented at the Annual Scientific Meeting of the Heart Failure Society of America. The study found that the BVA-100 test provided highly effective guidance for care of heart failure patients, with the test identifying variances in red blood cell volumes that provided an opportunity to evaluate and treat these patients.

Portfolio Pulse from Benzinga Newsdesk

October 11, 2023 | 12:04 pm

Daxor Corporation (NASDAQ:DXR), a leader in blood volume measurement technology, has been accepted into the National Institutes of Health (NIH) Catalyze Preclinical Services Program. This program supports preclinical development, including studies and activities needed to meet regulatory requirements for therapeutic and device submissions. The effort will be done in collaboration with two nationally recognized contract research organizations, to support the continued development of Daxor's non-nuclear fluorescent blood volume analyzer (BVA) device.

Portfolio Pulse from Benzinga Newsdesk

October 04, 2023 | 12:04 pm

Daxor Corporation has been awarded a $305K grant from the National Institutes of Health to develop blood volume guidance software for sepsis patients.

Portfolio Pulse from Benzinga Newsdesk

September 11, 2023 | 4:02 pm

Daxor Corporation has announced the publication of a research letter related to a heart failure trial with its BVA-100 product. The details of the trial and its results have not been disclosed in the news.

Portfolio Pulse from Benzinga Newsdesk

August 10, 2023 | 12:03 pm

Daxor Corporation (DXR) has announced further acquisitions and increased utilization of its BVA-100 blood volume diagnostic in the U.S. The company has expanded its blood volume analysis into five of six hospitals in the Southeast and increased utilization for clinical use at two sites. The recent launch of Daxor's ezBVA Lab service is expected to contribute significantly to the growth of BVA sales. A six-facility hospital system in Northern Kentucky and Southeastern Indiana has begun utilizing Daxor's ezBVA Lab service. Two additional hospitals have expanded the use of BVA testing.

Portfolio Pulse from Happy Mohamed

July 11, 2023 | 12:26 pm

All corporate logos and prices are for illustrative purposes only and are not a recommendation, an offer to sell, or a solicitation of an offer to buy any security.